Trial Profile
A Randomised Phase 2 Trial of Pemetrexed and Gefitinib Versus Gefitinib as First Line Treatment for Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2022
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 09 Oct 2019 Final overall survival and biomarker analysis results published in the Journal of Thoracic Oncology
- 16 Jan 2018 Status changed from active, no longer recruiting to completed.
- 25 Aug 2017 Planned End Date changed from 1 Oct 2017 to 1 Nov 2017.